BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Fibrex Medical Inc.: Peptide For Myocardial Infarction Proves Safe


4/6/2006 10:38:07 AM

VIENNA, Austria, April 6 /PRNewswire/ -- FIBREX Medical successfully completed a first dose in man study with its lead product, the anti-inflammatory peptide FX06. FX06 is developed to prevent reperfusion injury, an undesired inflammatory reaction after acute myocardial infarction. The now completed clinical trial measured tolerability and pharmacokinetics of FX06 in healthy volunteers. The study confirmed the excellent safety profile that has already been seen in experimental animal studies.

The clinical trial was performed at Medical University of Vienna, Austria. In total, 30 healthy participants received different doses of FX06 or a placebo, respectively. The results confirmed that even in high doses FX06 was very well tolerated with no adverse effects observed.

Rainer Henning, CEO of FIBREX, comments: "These very satisfying results allow us to progress rapidly with our development program for FX06. Already last year, in March 2005, we succeeded in demonstrating FX06's efficacy in preventing reperfusion in multiple animal models of several species with a highly acclaimed paper in Nature Medicine. Now, just a year later we have finished the phase I trial and are ready to move on to the clinical trial phase II. The preparation for this proof of concept study in patients with acute myocardial infarction is well advanced. In fact, we will enroll the first patient in the second quarter of 2006." This phase II clinical trial, labeled the FIRE study, will prove FX06's suitability for treating myocardial infarction in 140 patients in 20 centers in seven European countries. First results will become available in May 2007.

The rapid progress of FIBREX's drug development program has also been made possible by the successful completion of a series A financing-round in March 2005. Leading venture capitalists coled by Atlas Venture and Global Life Science Ventures invested $10 million to this aim.

www.fibrexmedical.com

FIBREX Medical

CONTACT: Contact: Dr. Rainer Henning, President & CEO, M +43-664-4159511,info@fibrexmedical.com www.fibrexmedical.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->